

FACTSHEET

April 17, 2025

COMPANY PROFILE

The Group are principally engaged in the manufacture and sale of edible collagen sausage casing products, collagen food products, collagen skin care products and polymer collagen medical biomaterials.

COLLAGEN SAUSAGE CASINGS

During 2024, the Group successfully developed and launched six new products of the collagen sausage casings series, namely "fried", "crispy", "fresh", "tender", "bright" and "colorful", and held new product promotional seminars and global investment promotion seminars to initiate industry exchanges. The new products earned unanimous customer praise, laying a solid foundation for promoting the comprehensive upgrade of collagen sausage casings products and covering market needs. To cope with the launch of new products, the Group also constantly strengthened and improved its production capacity. The plan of production capacity expansion formulated by the Group has basically been achieved, with the production capacity of collagen sausage casings reaching 7 billion metres.

COLLAGEN FOOD PRODUCTS

During 2024, the Group launched new products such as "Bo Bo Chicken (钵钵雞)" and "Beef Tripe (牛西肚)" in the research and development of collagen food products, which were well received by the market. In addition, the Group upgraded its products such as "ready-to-eat beef tendon", "collagen brown sugar ginger drink", "collagen oat drinks" and "collagen oat porridge", with the packaging and taste catering to the needs of consumers.

COLLAGEN SKINCARE PRODUCTS


For the research and development of collagen skincare products, the Group further increased its investment during 2024 by introducing a series of collagen skincare products, which have gradually enriched the product varieties and gained a favourable reputation. The development of collagen masks, skin nourishing lotions and multi-effective gel creams under the brands of "Luxianna", "COLL-FULL", "Collagen Family" and "coll-shine" has been improved and launched in the market gradually.

POLYMER COLLAGEN MEDICAL BIOMATERIALS

During 2024, the Group performed particularly well in the polymer collagen medical biomaterials segment, with the endotoxin content of the Group's medical collagen raw materials extracted through its proprietary technology being only 0.01EU/ml, which is better than the FDA's standard of 0.5EU/ml in the USA. The prospects of selling medical collagen raw materials were promising, representing an increase of 542.7% as compared with the Prior Year. Application has been made to the national regulatory authorities for the registration licence of "collagen bone filling biomaterials" as Class III medical device products, which is pending review and approval. The "oral post-operative medical collagen sponge (口腔術後醫用膠原蛋白海綿)" has passed the ethical review,

and will enter the clinical trial stage. The "medical collagen dressing (醫用膠原蛋白敷料)" and "small beauty needle (小美容針)" are in the process of physicochemical indicators testing and animal trial.

SHARE CHART



STOCK FUNDAMENTALS

ISIN	KYG8116M1087
Share Type	Ordinary
Bloomberg Code	829:HK
Ticker	829
Industry sector	Packaged Foods
Last Dividend	HKD 0.04
No. of shares	3,230,480,000
Market Cap	HK1.227B
52 week high	0.3350
52 week low	0.2600
Stock exchanges	Hong Kong Stock Exchange

KEY FIGURES

(RMB million, except where otherwise stated)	2024	2023
Revenue	1,016.8	1,110.4
Profit attributable to Owners of the Parent	26.7	31.2
Basic Earnings Per Share (RMB cents)	0.8	1.0
Dividend Per Share (HK cents)		
– Final	2	2
– Special (Final)	2	2
Net cash (used in) / from Operating Activities	(143.3)	176.4
Total Assets	2,829.2	2,957.3
Inventory Turnover Day – Raw Materials (days)*	61.1	37.7
Inventory Turnover Day – FG & WIP (days)*	223.4	156.7
Trade Receivables Turnover Day (days)*	61.3	64
Trade Payables Turnover Day (days)*	67.0	72.1

* Calculated based on the average value between the beginning of the year and the end of the year

	2024 Interim	2023 Interim
Revenue	452.4	509.3
Profit Attributable to Owners of the Parent	8.2	1.2
Basic Earnings Per Share (RMB cents)	0.25	0.04
Interim Dividend Per Share (HK cents)	-	-
Net cash (used in) / from Operating Activities	(149.5)	24.9
Total Assets	2,996.1	2,957.3
Inventory Turnover Day	60.6	37.7
– Raw Materials (days)		
Inventory Turnover Day	232.9	156.7
– FG & WIP (days)		
Trade Receivables Turnover Day (days)	66.4	64.0
Trade Payables Turnover Day (days)	62.3	72.1

Shenguan Holdings (Group) Limited

Mainland Office: No.39 Xijiang Fourth Road
 Wuzhou, Guangxi, People's
 Republic of China
 Tel and Fax: (86) 0774-2035538
 Email: shenguan@shenguan.com.cn

IR Contact

Wonderful Sky Financial Group
 Email: shenguan@wsfg.hk